Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 15/20 | 0.72 |
| ▸ | PDE2A | O00408 | 2/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3600684 | 0.84 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL3589256 | 0.84 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL3598902 | 0.84 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL3593827 | 0.79 | P2RX7 (0.74) | P2RX7 | |
| SCHEMBL3590862 | 0.78 | P2RX7 (0.89) | P2RX7CTSD | |
| SCHEMBL3587003 | 0.77 | P2RX7 (0.71) | P2RX7 | |
| SCHEMBL3591154 | 0.70 | P2RX7 (0.67) | P2RX7 | |
| SCHEMBL3591592 | 0.69 | P2RX7 (0.66) | P2RX7 | |
| SCHEMBL3593251 | 0.69 | P2RX7 (0.84) | P2RX7PDE2APDE10A | |
| SCHEMBL3600515 | 0.68 | P2RX7 (0.65) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709469-B2 | P2X7 receptor antagonists and methods of use | ABBOTT LABORATORIES (US) | 2010-05-04 | — | — | US | claimed |
| EP-1951689-A1 | P2X7 RECEPTOR ANTAGONISTS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-08-06 | — | — | EP | claimed |
| WO-2007056046-A1 | P2X7 RECEPTOR ANTAGONISTS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-05-18 | — | — | WO | claimed |
| US-20070105842-A1 | P2X7 receptor antagonists and methods of use | ABBVIE INC. | 2007-05-10 | — | — | US | claimed |
| US-7709469-B2 | P2X7 receptor antagonists and methods of use | ABBOTT LABORATORIES (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1951689-A1 | P2X7 RECEPTOR ANTAGONISTS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007056046-A1 | P2X7 RECEPTOR ANTAGONISTS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105842-A1 | P2X7 receptor antagonists and methods of use | ABBVIE INC. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105842-A1 | P2X7 receptor antagonists and methods of use | P2RX7, P2RX1, P2RX3 | P2RX7 1/4885PDE2A 998/4885PDE10A 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.